Effective October 10, 2017, the Board of Directors (the "Board") of AzurRx BioPharma, Inc. (the "Company") appointed Vern L. Schramm, Ph.D., to serve until the next annual meeting of stockholders or until his successor is elected and qualified.

Dr. Schramm is currently a Professor and Chairman of the Department of Biochemistry at the Albert Einstein College of Medicine, where he has taught for over thirty years. Prior to that, Dr. Schramm was a professor at Temple University School of Medicine. Dr. Schramm currently sits on the Metabalon Biochemistry Advisory Board and Sirtris Scientific Advisory Board, acts as a consultant for BioCryst Pharmaceuticals, and is the Scientific Co-founder of Pico Pharmaceuticals. Dr. Schramm has been elected to the National Academy of Sciences, has sat on several committees and advisory boards, presented at numerous events around the world, and has authored numerous original research publications. Dr. Schramm holds a B.S. in Bacteriology from South Dakota State College, a Master's Degree in Nutrition with a biochemistry emphasis from Harvard University, and a Ph.D. in Mechanism of Enzyme Action from Australian National University.

Except as disclosed in this Current Report on Form 8-K, there are no related party transactions between the Company and Dr. Schramm that would require disclosure under Item 404(a) of Regulation S-K, nor are there any further arrangements or understandings in connection with the appointment of Dr. Schramm to the Company's Board of Directors.